参考文献/References:
［1］Sampson J A. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity ［J］. American Journal of Obstetrics & Gynecology,1927,14(4): 93-94.
［2］Vigano P, Somigliana E, Parazzini F A. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer ［J］. Fertility and Sterility, 2007, 88(3): 588-593.
［3］何政星，王姝，冷金花，等．子宫内膜异位症恶变的临床风险分析 ［J］．中华妇产科杂志，2018，53（4）：282-284．
［4］Leslie AG,Marcela GC. Endometriosis-associated ovarian cancers ［M］.Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011.
［5］Thomsen L H, Schnack T H, Buchardi K A, et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review［J］. Acta Obstetricia et Gynecologica Scandinavica, 2017, 96(6): 761-778.
［6］刘崇东，娄彤，董靖．子宫内膜异位症恶变 ［J］．山东大学学报（医学版），2019，57（6）：27-32．
［7］Oral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours ［J］. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2003, 109(1): 97-101.
［8］Deligdisch L, Pénault-Llorca F, Schlosshauer P, et al. Stage I ovarian carcinoma:different clinical pathologic patterns ［J］. Fertility and Sterility, 2007, 88(4): 906-910.
［9］Vercellini P,De Matteis S,Somigliana E A,et al.Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis ［J］. Acta Obstetricia et Gynecologica Scandinavica, 2013, 92(1): 8-16.
［10］Bellelis P, Podgaec S, Bro M M. Environmental factors and endometriosis ［J］. Revista da Associao Médica Brasileira (English Edition), 2011, 57(4): 448-452.
［11］Herreros-Villanueva M, Chen C C, Tsai E M, et al. Endometriosis-associated ovarian cancer: What have we learned so far? ［J］. Clinica Chimica Acta, 2019, 493: 63-72.
［12］Suryawanshi S, Huang X, Elishaev E, et al. Complement pathway is frequently altered in endometriosis and Endometriosis-Associated ovarian cancer ［J］. Clinical Cancer Research, 2014, 20(23): 6163-6174.
［13］Km Z B. Aromatase:a key molecule in the pathophysiology of endometriosis and atherapeutic target ［J］. Fertility & Sterility, 1999, 72(6): 961-969.
［14］Arablou T, Kolahdouz-Mohammadi R. Curcumin and endometriosis: Review on potential roles and molecular mechanisms ［J］. Biomedicine & Pharmacotherapy, 2018, 97: 91- 97.
［15］Prowse A H, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer ［J］. International Journal of Cancer, 2006, 119(3): 556-562.
［16］Wiegand K C, Shah S P, AL-AGHA O M, et al. ARID1A mutations in Endometriosis-Associated ovarian carcinomas ［J］. New England Journal of Medicine, 2010, 363(16): 1532-1543.
［17］Oda K, Hamanishi J, Matsuo K, et al. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management ［J］. Gynecologic Oncology, 2018, 151(2): 381-389.
［18］Anglesion M S,Papadopoulos N,Ayhan A,et al.Cancer-Associated mutations in endometriosis without cancer ［J］. New England Journal of Medicine, 2017, 376(19): 1835-1848.
［19］Er T K, Su Yu-fa, Wu C C, et al. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer ［J］. Journal of Molecular Medicine - JMM, 2016, 94(7): 835-847.
［20］Zou Yang, Zhou Jiang-yan, Guo Jiu-bai, et al. The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis ［J］. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 2018, 809: 1-5.
［21］Meldrum C, Doyle M A, Tothill R W. Next-generation sequencing for cancer diagnostics:a practical perspective ［J］. Clinical Biochemist Reviews, 2011, 32(4): 177-180.
［22］Lim D, Murali R, Murray M P, et al. Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high-grade tumors ［J］. American Journal of Surgical Pathology, 2016, 40(3): 302-312.
［23］Chene G,Lamblin G,Le Bail-Carval K,et al. Prophylactic Salpingectomy or salpingo-oophorectomy as anovarian cancer prevention？ ［J］.Press Médicale,2015,44(3):317-323.
［24］Kawaguchi R, Tsuji Y, Haruta S, et al. Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma ［J］. Journal of Obstetrics and Gynaecology Research, 2008, 34(5): 872-877.
［25］Guo Sun-wei. Endometriosis and ovarian cancer: potential benefits and harms of screening and risk-reducing surgery ［J］. Fertility and Sterility, 2015, 104(4): 813-830.
［26］Mallen A, Soong T R, Townsend M K, et al. Surgical prevention strategies in ovarian cancer ［J］. Gynecologic Oncology, 2018, 151(1): 166-175.
［27］Nezhat F R, Apostol R, Nezhat C, et al. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention ［J］. American Journal of Obstetrics and Gynecology, 2015, 213(3): 262-267.
［28］Joo-Hyuk Son, Seokyoung Yoon, Seokyung Kim, et al. Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma ［J］. Obstet Gynecol Sci，2019;62(1):27-34.
［29］Kobayashi H, Yamada Y, Kawahara N, et al. Modern approaches to noninvasive diagnosis of malignant transformation of endometriosis ［J］. Oncology Letters, 2019, 17(1):1196-1202.
相似文献/References:
[1]苏慧明,徐燕,李晶,等.E-钙粘附素在子宫内膜异位症盆腔腹膜病灶的表达[J].中国计划生育和妇产科,2010,(01):0.
SU Hui-ming,XU Yan,LI Jing,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(2):0.
[2]李桂兰.青春期子宫内膜异位症的诊治进展[J].中国计划生育和妇产科,2010,(03):0.
[3]韦晓娜,覃红萍.孕三烯酮配伍小剂量米非司酮治疗子宫内膜异位症64例效果观察[J].中国计划生育和妇产科,2010,(04):0.
[4]李成龙,冷金花.子宫内膜异位症与雌、孕激素受体关系的研究进展[J].中国计划生育和妇产科,2010,(04):0.
[5]关铮.深部浸润型子宫内膜异位症相关问题探讨[J].中国计划生育和妇产科,2011,(04):0.
[6]张瑞霞,刘增娟,谢伟,等.腹腔镜诊断盆腔子宫内膜异位症及对不孕症患者的疗效观察[J].中国计划生育和妇产科,2012,(02):0.
ZHANG Rui-xia,LIU Zeng-juan,XIE Wei,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(2):0.
[7]梁寿珺,范余娟,黄尹,等.血管内皮生长因子+936TC基因多态性同子宫内膜异位症遗传易感性的Meta分析[J].中国计划生育和妇产科,2012,(04):0.
LIANG Shou-jun,FAN Yu-juan*,HUANG Yin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(2):0.
[8]范俊,栾少红,李晓林,等.口服避孕药在子宫内膜异位症治疗中的作用[J].中国计划生育和妇产科,2013,(02):0.
FAN Jun,LUAN Shao-hong,LI Xiao-lin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(2):0.
[9]柴明涵,董白桦.左炔诺孕酮宫内缓释系统的临床应用[J].中国计划生育和妇产科,2014,(03):0.
[10]李素红,冯春蝶,付秀虹,等.Treg细胞及Foxp3在子宫内膜异位症患者的表达及临床意义[J].中国计划生育和妇产科,2014,(04):0.
LI Su-hong,FENG Chun-die,FU Xiu-hong,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(2):0.